Biopharma Patients Pharmaceutical products Safety 
Clarivate
MARCH 14, 2024
With the introduction of a new CMC Intelligence entitlement to address post-approval changes, Clarivate now covers a broader range of the lifecycle of pharmaceutical products. Future research could focus on developing PFAS-free packaging materials that meet regulatory standards without compromising safety.
pharmaphorum
SEPTEMBER 28, 2022
In recent years, the biopharma market has become progressively complex. As a result, payers are feeling increased pressure to make the right decisions based on the perceived value of each product. HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers.
Expert insights. Personalized for you.
52 
Let's personalize your content